|
 |
HistrelinThis page contains recent news articles, when available, and an overview of Histrelin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Histrelin ( his-TREL-in) is a hormone similar to one normally released from the hypothalamus gland in the brain. Histrelin is used in the treatment of ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Histrelin (Systemic). - Feb 1, 2006 Histrelin( his-TREL-in) is a type of medicine called a gonadotropin-releasing hormone (GnRH) antagonist that lowers the male hormone testosterone in your ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Histrelin Subdermal Implant Effective Against Advanced Prostate Cancer - Apr 20, 2006 By Will Boggs, MD. NEW YORK APR 20, 2006 (Reuters Health) - A subdermal implant containing the gonadotropin-releasing hormone (GnRH) agonist histrelin ... Cancerpage.com Efficacy and Safety of Histrelin Subdermal Implant in Children with … - Feb 20, 2007 Erica A. Eugster MD * , William Clarke MD, Gad B. Kletter MD, Peter A. Lee MD, PhD, E. Kirk Neely MD, Edward O. Reiter MD, Paul Saenger MD, Dorothy Shulman ... Journal of Clinical Endocrinology and... Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R). - Dec 20, 2007 As a result of this announcement, Indevus' product VANTAS(R) (histrelin implant) will be the only 12-month implant for the palliative treatment of advanced ... Free with registration - PR Newswire - AccessMyLibrary.com Indevus Closes $105M Note Deal Backed by Sanctura Royalties - Aug 27, 2008 Other products marketed by Indevus include prostate cancer drug Vantas (histrelin implant), Supprelin LA (histrelin acetate implant) for central precocious ... BioWorld Online - BioWorld Online Indevus Announces Authorization For Approval Of VANTAS(R) In … - Jun 1, 2007 VANTAS(R) is a soft and flexible 12-month hydrogel implant that provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, ... Medical News Today - Medical News Today (press release) Indevus Announces FDA Approval Of SUPPRELIN-LA - May 4, 2007 ...(May 04, 2007)-- Indevus Pharmaceuticals announced that SUPPRELIN-LA (histrelin acetate subcutaneous implant) 50mg has been approved by the US Food and Drug ... Compliance Home - Compliance Home Valera submits NDA on Supprelin-LA to US FDA. - Jul 17, 2006 In addition to our currently marketed histrelin product, Vantas, this also includes Valstar (valrubicin), the only approved drug for certain urinary bladder ... $9.94 - Pharma Marketletter - Alacra Store Product news from the 05/08/07 News Brief - May 8, 2007 Indevus Pharmaceuticalssaid its Supprelin-LA (histrelin acetate subcutaneous implant) 50mg has been approved by the FDA. Supprelin-LA is indicated for the ... Medical Marketing & Media - Medical Marketing and Media Indevus Pharmaceuticals Announces Third Quarter Fiscal 2007 Financial... - Aug 7, 2007 ...designed to provide a continuous release over 12 months of approximately 65mcg/day of the gonadotropin releasing hormone (GnRH) analog histrelin. ... Free with registration - PR Newswire - AccessMyLibrary.com Indevus Pharmaceuticals to Announce Second Quarter Fiscal 2007 … - May 2, 2007 VANTAS and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; ... Free with registration - PR Newswire - AccessMyLibrary.com VANTAS Valera, Paladin registered, Canada (prostate cancer). - Mar 27, 2006 VANTAS is a sustained-release histrelin implant and comprises synthetic histrelin ... drug delivery system, histrelin hydrogel implant, histrelin hydrogel ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Article: Supprelin LA, Xyzal tablets.(New & Approved)(Drug overview) ... - Jul 1, 2007 New & Approved)(Drug overview) ... find Pediatric News articles. Supprelin LA (histrelin acetate, Indevus Pharmaceuticals Inc.) The Food and Drug Admin... Pay-Per-View - Pediatric News - HighBeam Research Implant halts early puberty - Dec 27, 2005 They report that an implant containing histrelin, a potent inhibitor of ... "The histrelin implant consistently suppresses clinical and laboratory ... TVNZ Press Release: Indevus Announces FDA Approval of SUPPRELIN(R)-LA. … - May 3, 2007 Supprelin-LA (histrelin acetate SC implant, from Indevus) has been made ... News) today announced that SUPPRELIN -LA (histrelin acetate subcutaneous . ... Pay-Per-View - PR Newswire - HighBeam Research Israeli implant prevents early onset of puberty - Jan 15, 2006 The histrelin implant is being touted as a replacement for the current method to curb central ... The implant containing histrelin, a potent agonist of the ... Israel 21C Indevus Pharmaceuticals, Inc. (IDEV) Two Year Study Confirms … - May 7, 2008 Indevus Pharmaceuticals, Inc. announced positive results of the ongoing Phase III extension study of SUPPRELIN(R) LA (histrelin acetate), ... Lifescience-online Are you there, God? Can you put off my period? - Dec 30, 2005 The implant would contain histrelin, a hormone that bullies the hormones that ... (Some girls already use histrelin in injection form; those tested in ... Salon Hormone-blocking implant halts too-early puberty - Dec 26, 2005 They report that an implant containing histrelin, a potent inhibitor of ... "The histrelin implant consistently suppresses clinical and laboratory ... RedOrbit Press Release: Indevus Pharmaceuticals Inc Implant Launched and … - Jun 28, 2007 Food and Drug Administration approved Supprelin LA (histrelin acetate ... Supprelin-LA (histrelin acetate SC implant, from Indevus) has been made available ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Indevus to Announce Second Quarter Fiscal 2008 … - Apr 23, 2008 Food and Drug Administration approved Supprelin LA (histrelin acetate subcutaneous implant ... Comment: Safety and efficacy of Supprelin LA was based on two ... Pay-Per-View - PR Newswire - HighBeam Research International Approvals: HeartMate II, Vantas, Urgent PC - Nov 29, 2005 The Danish Medicines Agency has approved a 1-year histrelin implant for ... Histrelin is a synthetic luteinizing hormone-releasing hormone (LHRH) agonist. ... Medscape Press Release: Two Year Study Confirms SUPPRELIN(R) LA Implant … - May 5, 2008 SUPPRELIN LA is a currently marketed ... histrelin to treat central precocious puberty. It employs ... See all results Or, try our Advanced Search ... Pay-Per-View - PR Newswire - HighBeam Research International Approvals: Vantas, Quinvaxem, Nexavar - Apr 10, 2006 April 10, 2006 — Health Canada has approved a 12-month histrelin implant ... Histrelin is a synthetic luteinizing hormone-releasing hormone (LHRH) agonist. ... Medscape Testosterone Suppression Speedily Reversed - Mar 23, 2005 The researchers thus point out that histrelin implants allow simple implementation of intermittent hormonal therapy. However, because of the long-term ... Cancerpage.com FDA Approvals: Supprelin LA, AzaSite, Invega - Jun 15, 2007 On May 3, the FDA approved a histrelin acetate 50-mg subcutaneous implant (Supprelin ... A previously approved histrelin 50-mg subcutaneous implant (Vantas, ... Medscape Prostate with grief: aging baby boomers urgently need innovative … - Mar 7, 2005 The Food & Drug Administration also recently approved the long-acting LHRH agonist histrelin (Vantas, Valera Pharmaceuticals) implant for the palliative ... Free with registration - Drug Topics - AccessMyLibrary.com Prostate Cancer Updates - Apr 8, 2006 The Food & Drug Administration also recently approved the long-acting LHRH agonist histrelin (Vantas, Valera Pharmaceuticals) implant for the palliative ... UroToday International Journal Press Release: Indevus Announces Launch of SUPPRELIN(R) LA for … - Jun 25, 2007 SUPPRELIN LA is a currently marketed ... histrelin to treat central precocious puberty. It employs ... See all results Or, try our Advanced Search ... Pay-Per-View - PR Newswire - HighBeam Research Implant provides long-acting treatment for prostate cancer. - Jan 10, 2005 The implant consists of a 50-mg histrelin drug core inside a nonbiodegradable, cylindrically shaped hydrogel reservoir, said Martin Dineen, M.D., ... $9.94 - Drug Topics - Alacra Store Press Release: Indevus Announces Receiving FDA Approval of … - May 4, 2007 Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV - News) today announced that SUPPRELIN -LA (histrelin acetate subcutaneous implant) 50mg has been approved by ... Pay-Per-View - M2 Presswire - HighBeam Research Indevus Announces Launch of SUPPRELIN(R) LA for Central Precocious … - Jun 25, 2007 LEXINGTON, Mass., June 25 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. today announced the launch and availability of SUPPRELIN(R) LA (histrelin ... Free with registration - PR Newswire - AccessMyLibrary.com Indevus licenses Vantas to Orion in Europe. - Apr 14, 2008 The USA's Indevus Pharmaceuticals has granted Finnish drugmaker Orion rights to market Vantas (histrelin acetate subcutaneous implant) throughout Europe, ... $9.94 - Pharma Marketletter - Alacra Store Valera Pharmaceuticals Completes Phase III Study of Its Twelve-Month ... - Apr 6, 2006 Histrelin acetate was previously approved by the FDA and marketed during the 1990's, under the brand name Supprelin, as a daily injection for treating CPP. ... RedOrbit Paladin Reports 2005 Second Quarter Results-Paladin Increases 2005 … - Jul 28, 2005 Trelstar ® compliments our established urology franchise with Oxytrol ® and Vantas TM (Histrelin Hydrogel Implant), a unique, once-yearly LHRH agonist ... ccnmatthews.com Paladin Reports Record Second Quarter Results and Provides Upward … - Aug 3, 2006 In the third quarter, we will be launching Trelstar ® (LHRH) and Vantas ® (Histrelin Hydrogel Implant) for advanced prostate cancer. ... ccnmatthews.com Company Profile Report - Apr 14, 2007 Supprelin-LA (Histrelin). Oncology. Urology. Prostate Cancer. Palliative Agents ... Vantas (Histrelin). Urinary Bladder Cancer. Transitional Cell Carcinoma ... $50.00 - Revere Reports - Revere Stock Market Update, IPO profiles, Earnings Call Transcripts,... - Mar 14, 2005 Histrelin, a powerful inhibitor of testosterone production, ... VP002 is an implant utilizing Hydron Technology to deliver histrelin over a 12-month period ... 123Jump.com Implant delivers LHRH agonist for 12 months: Valera Pharmaceuticals, ... - May 1, 2005 Valera Pharmaceuticals, Inc., has introduced histrelin implant (Vantas), ... Vantas is a flexible, hydrogel implant, which delivers histrelin for 12 months. ... Free with registration - Urology Times - AccessMyLibrary.com Article: Implant aids treatment of distressing condition.(RESEARCH … - May 1, 2006 Histrelin acetate was previously approved by the FDA and marketed during the 1990s, under the brand name Supprelin, as a daily injection for treating CPP. ... Pay-Per-View - Biomedical Materials - HighBeam Research Indevus to acquire Valera for $120M plus possible milestones. - Dec 18, 2006 It markets the histrelin product, Vantas, for advanced prostate cancer and has multiple products in clinical development, including Supprelin-LA (histrelin) ... $9.94 - Pharma Marketletter - Alacra Store Emerging Markets Consulting, LLC. : Emerging Equity Alerts. - Dec 13, 2006 Its products include Vantaso, a 12-month implant for the palliative treatment of advanced prostate cancer that delivers histrelin, a luteinizing ... $4.95 - M2 Presswire - ECNext VANTAS Valera registered, Denmark (prostate cancer). - Dec 5, 2005 VANTAS is a sustained-release histrelin implant and comprises synthetic histrelin delivered via Valera's proprietary subcutaneous hydrogel implant ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Implant delivers LHRH agonist for 12 months: Valera Pharmaceuticals, ... - May 1, 2005 Valera Pharmaceuticals, Inc., has introduced histrelin implant (Vantas), an LHRH agonist for the palliative treatment of advanced prostate cancer. $4.95 - Urology Times - ECNext Indevus Pharmaceuticals Announces Second Quarter Fiscal 2007 … - May 9, 2007 On May 3, 2007, the Company announced that SUPPRELIN(R) LA (histrelin acetate subcutaneous implant) 50mg was approved by the FDA. ... Free with registration - PR Newswire - AccessMyLibrary.com Supprelin LA, Xyzal tablets.(New & Approved)(Drug overview) - Jul 1, 2007 The Food and Drug Administration approved Supprelin LA (histrelin acetate subcutaneous implant) 50 mg for treatment of central precocious puberty in ... Free with registration - Pediatric News - AccessMyLibrary.com Supprelin-LA Receives Full Approval - May 7, 2007 The FDA has approved Indevus Pharmaceuticals' Supprelin-LA (histrelin acetate) 50 mg once-yearly subcutaneous implant for the treatment of central ... Facts and Comparisons Press Release: Morning Alert for Indevus Pharmaceuticals Inc. - M2 … - Jun 27, 2007 Indevus Pharmaceuticals, Inc. announced Monday 2007-06-25 the launch and availability of SUPPRELIN LA (histrelin acetate) subcutaneous implant, 50mg, ... Pay-Per-View - M2 Presswire - HighBeam Research Paladin annonce ses résultats du deuxième trimestre et révise à la … - Aug 3, 2006 Au cours du troisième trimestre, nous lancerons Trelstar(MD) (LHRH) et Vantas(MD) (implant d'hydrogel Histrelin) pour traiter le cancer avancé de la ... ccnmatthews.com Indevus and FDA Agree on Path Forward for NEBIDO(R) - Sep 26, 2008 ...spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, ... RedOrbit Stocks in focus for Friday - MarketWatch - May 3, 2007 ...inner aspect of the upper arm, and is designed to provide a continuous release of a certain amount the gonadotropin releasing hormone analog histrelin. ... MarketWatch Paladin annonce ses résultats du deuxième trimestre de 2005-Paladin … - Jul 28, 2005 ...de Paladin dans le domaine de l'urologie en s'intégrant aux activités promotionnelles liées à Oxytrol(MD) et à Vantas MC (implant hydrogel Histrelin), ... ccnmatthews.com Stocks to Watch: Kodak, Starbucks and Wsahington Post - May 4, 2007 ...inner aspect of the upper arm, and is designed to provide a continuous release of a certain amount the gonadotropin releasing hormone analog histrelin. ... FOXNews Indevus Pharmaceuticals Announces Completion of Enrollment in Phase … - Aug 22, 2008 ...spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, ... FierceBiotech Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 … - Aug 5, 2008 ...spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, ... prnewswire.com Press Release: Arginox Appoints Robert Terifay as President and Chief... - Jan 6, 2006 Histrelin Acetate, Injection Patient Medication Advisory. Clinical Reference Systems; December 1, 1997 ; 700+ words ...Histrelin Acetate, Injection Patient ... Pay-Per-View - PR Newswire - HighBeam Research Indevus Pharmaceuticals Announces Issuance of US Patent for … - Aug 13, 2008 ...spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, ... Genetic Engineering News - Genetic Engineering News (press release) Indevus Announces Agreement With Teva To Develop Pagoclone For … - Oct 1, 2008 ...spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, ... Medical News Today - Medical News Today (press release) 125 Indevus Sales Representatives to Provide Community Service in … - Mar 20, 2008 ...spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, ... RedOrbit Indevus Presents Successful Phase III NEBIDO(R) Data at American … - May 20, 2008 ...spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, ... RedOrbit Indevus Pharmaceuticals and Valera Pharmaceuticals Joint Acquisition ... - Dec 12, 2006 Vantas delivers the LHRH agonist histrelin continuously over a one-year period. The product was approved for marketing in the US in late 2004 and its ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com åŠ æ‹¿å¤§å?‘布《食å“?è?¯å“?法规》 - Oct 10, 2006 ...组氨瑞林(Histrelin)å?Šå…¶ç›?ç±»-是在患者皮下注射的ã€?用于缓解治疗的黄体è?·å°”è’™é‡Šæ”¾æ¿€ç´ çš„å?ˆæˆ?类似物。该è?¯ä½¿ç”¨å¯¹è±¡æ˜¯ä¾?èµ–è?·å°”蒙的高龄å‰?列腺癌患者。 ... ä¸å›½ç»?济网 Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotid... - Nov 28, 2007 VANTAS, SUPPRELIN LA and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: Indevus Pharmaceuticals Scheduled to Present at … - May 15, 2008 ...spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, ... Pay-Per-View - PR Newswire - HighBeam Research The 'CAP' is out of the bag; should you participate? CMS's Competitive... - Aug 1, 2005 Histrelin (Vantas) also is excluded initially, since it is reported with a nonspecific code. * CMS is going to allow the CAP vendor to charge the patient ... Free with registration - Urology Times - AccessMyLibrary.com Indevus Pharmaceuticals Announces Retirement of David B. Sharrock … - Oct 22, 2007 VANTAS, SUPPRELIN LA and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; ... Free with registration - PR Newswire - AccessMyLibrary.com Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2007 … - Jul 31, 2007 VANTAS and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; ... Free with registration - PR Newswire - AccessMyLibrary.com Indevus Appoints Industry Veteran Kurt Lewis as Senior Vice President... - Jun 29, 2007 VANTAS and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; ... Free with registration - PR Newswire - AccessMyLibrary.com Valera Pharmaceuticals Submits NDA for SUPPRELIN-LA, a 12-Month … - Jul 6, 2006 SUPPRELIN-LA has been designed to provide the continuous 12-month administration of a controlled dose of histrelin, a potent synthetic nonapeptide agonist ... Free with registration - Business Wire - AccessMyLibrary.com Research and Markets : Sales of Abarelix For the Treatment of... - Jan 15, 2007 Additionally, in October 2004 FDA approved histrelin for the palliative treatment of advanced prostate cancer. Finally, leuprolide was approved by FDA in ... Genetic Engineering News - Genetic Engineering News (press release) Indevus to Present at the 2007 FBR Growth Conference. - May 23, 2007 VANTAS and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; ... Free with registration - PR Newswire - AccessMyLibrary.com Indevus to Present at the Citigroup Healthcare Conference. - May 11, 2007 VANTAS and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; ... Free with registration - PR Newswire - AccessMyLibrary.com Meeting Highlights From CHMP, 19-22 February 2007 - Second Mock-up … - Feb 19, 2007 The Committee started a referral procedure for Vantas 50 mg implant (histrelin acetate), from Valera Pharmaceuticals Ltd, Ireland. ... Medical News Today - Medical News Today (press release) Look for these coding, reimbursement changes in 2006: new CPT codes … - Dec 1, 2005 Eligard, Viadur), goserelin acetate (Zoladex), histrelin (Vantas), and others--instead of codes 90765 to 90779 or the corresponding "G" codes. ... Free with registration - Urology Times - AccessMyLibrary.com The Hydron Implant Technology - Jan 20, 2006 Israel21c.org is reporting that a group of Israeli researchers have successfully tested an implant containing histrelin, a potent agonist of the ... Medgadget.com Indevus Pharmaceuticals to Present at Upcoming Investor Conferences. - Sep 17, 2007 VANTAS, SUPPRELIN LA and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; ... Free with registration - PR Newswire - AccessMyLibrary.com Leuprolide (Systemic). - Jul 28, 2005 Tell your doctor if you have ever had any unusual or allergic reaction to leuprolide, buserelin, gonadorelin, histrelin, nafarelin, or to benzyl alcohol, ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com EMEA CMPH Use Adopts 5 Positive Opinions Recommending The … - May 29, 2007 The CHMP finalised a referral procedure for Vantas 50 mg implant (histrelin acetate), from Valera Pharmaceuticals Ltd, Ireland, concluding that the benefits ... Medical News Today - Medical News Today (press release) TBIO, TES, VE, VLRX, XTLB, DBMI have also been added to naked short … - Feb 14, 2006 Its primary product is Vantas, a 12-month implant for the palliative treatment of advanced prostate cancer that delivers histrelin, a luteinizing ... Free with registration - M2 Presswire - AccessMyLibrary.com Valera Finishes Early Puberty Study - Apr 10, 2006 The implant would administer a controlled dose of histrelin acetate, which was previously approved by the FDA and marketed during the 1990's, ... RedOrbit FDA submissions, approvals and other actions: July 2006.(Table) - Aug 14, 2006 Valera Supprelin-LA Implanted product that Pharmaceuticals provides 12-month Inc. * delivery of histrelin Y's YSPSL Molecule resulting from Therapeutics ... Free with registration - Bioworld Financial Watch - AccessMyLibrary.com Morning Alert for Indevus Pharmaceuticals Inc. - Jun 27, 2007 Indevus Pharmaceuticals, Inc. announced Monday 2007-06-25 the launch and availability of SUPPRELIN LA (histrelin acetate) subcutaneous implant, 50mg, ... Free with registration - M2 Presswire - AccessMyLibrary.com Press Release: Indevus Pharmaceuticals Licenses European Rights for … - Apr 3, 2008 Corporation granting Orion the rights to market VANTAS(R) (histrelin acetate subcutaneous implant) throughout Europe as well as certain other countries. ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Indevus Pharmaceuticals to Present at Upcoming... - Oct 28, 2008 ...spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, ... Pay-Per-View - PR Newswire - HighBeam Research Prostate Cancer; Some rights to implant to treat prostate cancer in... - Mar 28, 2005 Utilizing Valera's proprietary hydron technology, Vantas is designed to deliver an even predetermined dose of histrelin over a 12-month period. ... Pay-Per-View - Pain & Central Nervous System Week - Factiva, from Dow Jones Indevus Announces FDA Approval of SANCTURA(R) XR. - Aug 6, 2007 VANTAS and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; ... $4.95 - PR Newswire - ECNext Paladin Labs Inc.: Health Canada Requests Additional Information on … - Jun 16, 2005 Directorate (TPD) of Health Canada that its New Drug Submission (NDS) for Vanats(R) (Histrelin Hydrogel Implant) will not be approved at this time. ... $4.95 - Business Wire - ECNext Supprelin-LA. - Jun 1, 2007 A once-yearly subcutaneous implant containing histrelin (Supprelin-LA, Indevus) was approved for the treatment of central precocious puberty. ... $9.94 - Formulary - Alacra Store Finance; Paladin reports record second-quarter results and provides … - Sep 5, 2006 In the third quarter, we will be launching Trelstar and Vantas (Histrelin Hydrogel Implant) for advanced prostate cancer. This will make us the only company ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Competitors by Product Report - Apr 14, 2007 Products:. Supprelin-LA (Histrelin). Abbott Laboratories (ABT) Products:. Lupron/Lupron Depot Series (Leuprolide Acetate). Novartis AG (ADR) (NVS) Products: ... $75.00 - Revere Reports - Revere FDA submissions, approvals and other actions: July 2006. - Aug 14, 2006 Inc. * delivery of histrelin Y's YSPSL Molecule resulting from Therapeutics the fusion of P-selectin Inc. * glycoprotein ligand-1 to human IgG1 ... Pay-Per-View - Bioworld Financial Watch - Factiva, from Dow Jones Press Release: Indevus Pharmaceuticals to Present at Upcoming... - Sep 17, 2007 VANTAS, SUPPRELIN LA and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Market Commentary on Valera Pharmaceuticals. - M2 … - Dec 12, 2006 Its FDA-approved Vantas administers histrelin to patients with prostate cancer. In addition, Valera is developing several drug candidates to treat ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Indevus To Present at UBS Global Generic and Specialty... - May 1, 2007 VANTAS and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; ... Pay-Per-View - PR Newswire - HighBeam Research Certain bruising patterns suggest abuse.(Behavioral Pediatrics) |... - Mar 1, 2005 Pediatric News; July 1, 2007 ; 700+ words ... ... hormone analog histrelin. The implant is inserted in the upper aspect of the arm. ... Pay-Per-View - Pediatric News - HighBeam Research Press Release: Oasmia Enters New Important License Agreement for … - Apr 1, 2008 Supply and Distribution Agreement with Orion Corporation granting Orion the rights to market VANTAS(R) (histrelin ... octreotide for acromegaly, ... Pay-Per-View - PR Newswire - HighBeam Research Valera Pharmaceuticals Receives PDUFA Date for SUPPRELIN-LA, a … - Sep 7, 2006 ...has been designed to provide the continuous 12-month administration of a controlled dose of histrelin. The multi-center, open-label Phase III study of ... $4.95 - Business Wire - ECNext Indevus Pharmaceuticals To Present at RBC Capital Markets Conference. - Dec 5, 2007 VANTAS, SUPPRELIN LA and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; ... $4.95 - PR Newswire - ECNext Press Release: Indevus to Present at the Sixth Annual JMP Securities ... - May 15, 2007 VANTAS and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; ... Pay-Per-View - PR Newswire - HighBeam Research |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |